Sirtris Pharmaceuticals soars on buyout by Glaxo
Shares of Sirtris Pharmaceuticals Inc.(Nasdaq:SIRT) are rocketing in pre-market trading after the biopharmaceutical company said after Tuesday’s close that it will be acquired by healthcare goliath GlaxoSmithKline (NYSE:GSK) for approximately $720 million through a cash tender offer of $22.50 per share.
Shares soared 82%, or $9.98, to $22.21 in pre-market trading. For detailed price information and recent news stories about Sirtris Pharmaceuticals, click SIRT.
